免疫检查点抑制剂用于进展期胃癌围手术期治疗的中国专家共识(2024版)

Chinese expert consensus on immune checkpoint inhibitors for perioperative treatment of advanced gastric cancer(2024 edition)

近年来,免疫治疗改变了晚期胃癌的治疗格局,研究者尝试将免疫治疗前移,开展一系列围绕局部进展期胃癌患者围手术期免疫联合治疗的探索性和确证性临床研究。已有研究结果显示:免疫治疗可提高患者的病理学缓解,但对长期生存获益仍不明确。目前临床工作中局部进展期胃癌患者围手术期免疫治疗应用广泛,然而其适应证、适用人群、治疗周期以及相关安全性管理,尚缺乏统一标准和规范。中国抗癌协会胃癌专业委员会组织国内胃癌研究领域的多学科专家,汇总国内外最新指南和循证证据,并结合我国临床实际,共同研讨制订《免疫检查点抑制剂用于进展期胃癌围手术期治疗的中国专家共识(2024版)》,旨在进一步提高胃癌临床一线医师对局部进展期胃癌围手术期免疫治疗应用的认知,提高我国胃癌诊断与治疗水平。

In recent years,the immunotherapy has changed the treatment pattern of advanced gastric cancer.The investigators attempt to identify the efficacy and safety of perioperative immunotherapy by conducting a series of exploratory and confirmatory clinical studies in patients with locally advanced gastric cancer(LAGC).Preliminary results show that the addition of immunotherapy could improve the pathological remission of patients,but the long-term survival benefits remain unclear.At present,perioperative immunotherapy has been widely used in patients with LAGC,but there is a lack of unified standards and norms for its indications,target audience,treatment cycle,and related safety management.The Gastric Cancer Professional Committee of China Anti-Cancer Association organizes multidisciplinary experts in the field of gastric cancer in China to summarize the latest guidelines and research evidence,and formulate the Chinese Expert Consensus on Immune Checkpoint Inhibitors for Perioperative Treatment of Advanced Gastric Cancer(2024 Edition)based on clinical practice and joint discussion.The aims of this consensus are to improve the application of perioperative immunotherapy of LAGC for clinicians,especially clinicians in primary hospitals,and to improve the diagnosis and treatment.